{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-038055","form_type":"8-K","ticker":"ANTX","cik":"0001880438","company_name":"AN2 Therapeutics, Inc.","filed_at":"2024-03-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:26.218528+00:00","generated_at":"2026-06-04T06:37:04.442470+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"AN2 Therapeutics reports FY2023 net loss of $64.7M; Phase 2/3 trial paused, topline expected summer 2024","bullets":["Net loss FY2023 $64.7M vs $41.0M prior year; Q4 net loss $16.9M vs $11.8M.","Cash, equivalents and investments $134.5M at Dec 31, 2023.","Phase 3 enrollment in epetraborole TR-MAC trial paused voluntarily Feb 2024 due to potentially lower efficacy; Phase 2 topline results expected summer 2024.","Plan to discuss Phase 2/3 data with FDA; no safety concerns prompted pause.","Executed license from UGA for Chagas disease candidate AN2-502998; Gates Foundation grant for TB/malaria."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-038055","json":"https://secwatch.observer/filing/0000950170-24-038055.json","markdown":"https://secwatch.observer/filing/0000950170-24-038055.md","text":"https://secwatch.observer/filing/0000950170-24-038055.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1880438/000095017024038055/0000950170-24-038055-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1880438/000095017024038055/antx-20240328.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T06:37:04.442470+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"f29c3b11853a02faa9f71593dc72722e93b81224","claim":"AN2 Therapeutics, Inc. reported the fourth quarter and year ended December 31, 2023 results: net income Net loss for the full year 2023 was $64.7 million, compared to $41.0 million in the prior year. Net loss for the fourth.","evidence_excerpt":"AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseases with high unmet needs, today reported financial results for the fourth quarter and year ended December 31, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1880438/000095017024038055/0000950170-24-038055-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter and year ended December 31, 2023"},{"label":"Net income","value":"Net loss for the full year 2023 was $64.7 million, compared to $41.0 million in the prior year. Net loss for the fourth"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}